Icotrokinra is a targeted oral peptide that selectively blocks the IL-23 receptor, reducing inflammatory signaling. It is approved for moderate-to-severe plaque psoriasis and is being studied for other immune-mediated diseases, including psoriatic arthritis and inflammatory bowel diseases.